Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,613 across all filing types
Latest filing 2026-05-29 Audit Report / Informat…
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
114年第4季財務報告書 — 202504_1734_AIC.pdf
Audit Report / Information Classification · 96% confidence The document is the independent auditors’ report together with detailed parent company only financial statements and notes for the years ended December 31, 2025 and 2024. It is not an announcement of a report (it contains the full audited financial statements), nor a full annual report with MD&A – it is specifically the standalone audit opinion and financial statement schedules. This fits the definition of an Audit Report / Information (AR). FY 2025
2026-05-29 English
114年第4季財務報告書 — 202504_1734_AIA.pdf
Audit Report / Information Classification · 90% confidence The document is the consolidated financial statements for the years ended December 31, 2025 and 2024 together with the Independent Auditors’ Report and Representation Letter. It contains the audit opinion, basis for opinion, key audit matters, and full financial statements (balance sheet, income, cash flows, notes). This matches a standalone Audit Report / Information filing, not an announcement or a broader annual report with MD&A. Therefore, it is classified as AR. FY 2025
2026-05-29 English
115年05月僑外投資持股
Regulatory Filings Classification · 90% confidence The document is a statutory foreign and mainland China investor shareholding statistics table (“僑外及大陸地區投資人投資持股情形統計表”) filed on the Open Information Observatory of Taiwan. It is a periodic regulatory disclosure of aggregated shareholdings by foreign and mainland investors, not an earnings release, proxy, or an annual/interim report. It does not report a specific major investor crossing a threshold but is a general compliance form. This fits the fallback category of general regulatory announcements: Regulatory Filings (RNS).
2026-05-22 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 90% confidence The document is a Q1 (“115年1季申報作業”) financial disclosure showing detailed actual financial data (investment amounts, share ratios, profit/loss) for overseas subsidiaries of the listed company 杏輝藥品工業. It is part of the company’s interim/quarterly reporting, not a simple announcement of publication or a full annual report. Therefore, it fits the Interim/Quarterly Report category. Q1 2026
2026-05-15 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 90% confidence The document is a regulatory disclosure on the public information platform (公開資訊觀測站) showing specific investment details into Mainland China for Q1 of year 115. It contains tables of remitted amounts, methods of investment, equity stakes, and related footnotes. It is not a full quarterly interim report (no P&L or B/S), not an earnings release or management presentation, nor a change-in-management, proxy, or dividend notice. It is a standalone regulatory compliance filing disclosing cross‐border investment details, which falls under the general Regulatory Filings category (RNS).
2026-05-15 Chinese
115年第1季財務報告書 — 202601_1734_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a consolidated financial report for the first quarter (民國115及114年第1季) including full interim financial statements (balance sheet, income statement, cash flows, notes) and an auditor’s review report. It is substantive financial data for a period shorter than a full year (Q1), not merely an announcement or certification. Therefore it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.